Pharmaceutical Research & Drug Development – Page 16

Design space poorly justified during validation planning – data expectations for filings

Addressing Inadequately Supported Design Space in Validation Planning: A Comprehensive Playbook In the complex world of pharmaceutical manufacturing, ensuring the robustness of your validation planning is crucial. One of the…

Process variability exceeds limits during validation planning – regulatory scrutiny risk

Managing Process Variability during Validation Planning for Regulatory Compliance In the pharmaceutical manufacturing landscape, exceeding process variability limits during validation planning presents a significant challenge that can raise regulatory scrutiny…

Yield loss during optimization during pilot scale – regulatory scrutiny risk

Identifying yield loss during pilot scale operations begins with observant monitoring of specific symptoms or signals. Here are common indicators that can suggest yield-related issues:Click to read the full article.

Control strategy inadequate during development studies – data expectations for filings

Recognizing signs of inadequate control strategies is crucial for timely interventions. Here are some common symptoms:Click to read the full article.

CPPs not well defined during regulatory submission – data expectations for filings

Identifying symptoms and signals early can help prevent larger issues in regulatory submissions. Signs of poorly defined CPPs often manifest as:Click to read the full article.

Control strategy inadequate during regulatory submission – process robustness improvement framework

Understanding the root causes of control strategy inadequacies is crucial for corrective and preventive actions. Causes can generally be categorized as follows:Click to read the full article.

Design space poorly justified during regulatory submission – process robustness improvement framework

Identifying the symptoms of poorly justified design space is crucial for early mitigation. Key indicators include:Click to read the full article.

Design space poorly justified during validation planning – ICH Q8/Q11 alignment strategy

Strategic Approaches for Addressing Poor Justification of Design Space During Validation Planning In the pharmaceutical industry, the successful transition from formulation development to commercial production hinges on a well-defined design…

Yield loss during optimization during pilot scale – process robustness improvement framework

Detecting yield loss at pilot scale can often be subtle yet critical. Symptoms may manifest as:Click to read the full article.

CPPs not well defined during lifecycle optimization – ICH Q8/Q11 alignment strategy

Aligning Critical Process Parameters During Lifecycle Optimization in Pharma In the fast-paced world of pharmaceutical manufacturing, failure to clearly define Critical Process Parameters (CPPs) during lifecycle optimization can lead to…

CPPs not well defined during regulatory submission – regulatory scrutiny risk

Recognizing symptoms of poorly defined CPPs is vital for timely remediation. Here are observable indicators that may suggest a lack of clarity in CPP definitions:Click to read the full article.

CPPs not well defined during development studies – ICH Q8/Q11 alignment strategy

Identifying signals of inadequately defined CPPs early in the development phase is crucial to minimizing risk. Symptoms may manifest in various stages of production and analytical testing:Click to read the…